Condition

Solid Tumors and Hematologic Malignancy

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions8

Lead sponsors shown1

Clinical trials

3 shown

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesNCT02712905 · 2016-05-05

TERMINATED

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesNCT02431260 · 2015-04-14

TERMINATED

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsNCT02355431 · 2014-12-01

WITHDRAWN

Common interventions

all-trans retinoic acid (ATRA)DRUG1azacitidineDRUG1erlotinibDRUG1INCB054329 MonotherapyDRUG1INCB059872DRUG1ItacitinibDRUG1nivolumabDRUG1placeboDRUG1

Leading sponsors

Incyte Corporation3

Trial status mix

TERMINATED2

WITHDRAWN1

Phase mix

PHASE23

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.